SLRN Rasio cepet Acelyrin, Inc.

This price chart on the GURU.Markets platform demonstrates the price action of Acelyrin, Inc. (SLRN), where the current coefficient is 18.40. Acelyrin, Inc. (SLRN) is developing advanced methods to combat immune pathologies by blocking destructive proteins to enhance treatment safety. Growth is expected from the Phase 3 trial results of isobelimab and new contracts. Meanwhile, the business is relying on its own capital reserves, having temporarily pivoted away from mergers and streamlined its project pipeline.

The quick ratio assesses a company's ability to settle short-term debts without liquidating inventory. By analyzing current quick liquidity, an investor gains visibility into the actual balance of cash and accounts receivable. This metric is critically sensitive to the rate of capital burn, as it excludes illiquid assets from the calculation. For Acelyrin, Inc. (SLRN), such financial stability offsets the risks associated with outsourcing clinical trials to contract research organizations (CRO).